{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:49:09Z","timestamp":1794019749747,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372056"],"award-info":[{"award-number":["82372056"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273299"],"award-info":[{"award-number":["82273299"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403533"],"award-info":[{"award-number":["82403533"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","award":["R07019"],"award-info":[{"award-number":["R07019"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Science and Technology Department","doi-asserted-by":"publisher","award":["2020B1111170006"],"award-info":[{"award-number":["2020B1111170006"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Senescence plays a critical role in prostate cancer, influencing disease onset and progression. However, the alterations of senescence-associated genes during prostate cancer progression and their potential value in predicting disease advancement remain to be further elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>117 machine learning methods were applied to construct the senescence-related gene signature (SRGS). Temporal trajectory analysis based on bulk and single-cell transcriptomic datasets was performed to link SRGS with prostate cancer progression. Functional validations of PCNA were conducted both in vitro and in vivo to support our analytical findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using 117 machine learning methods, we developed the SRGS, which demonstrated robust predictive capability across multiple cohorts, including our own cohort of 90 patients. The SRGS also showed strong potential in predicting overall survival in patients treated with second-generation AR inhibitors. Temporal trajectory analysis of bulk RNA-seq and single-cell data revealed the biological significance of SRGS and identified Proliferating Cell Nuclear Antigen (PCNA) as a potential driver of PCa progression. Pharmacological inhibition of PCNA with AOH1996 significantly suppressed tumor growth and enhanced the efficacy of androgen deprivation therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We developed the SRGS that effectively predicts prostate cancer prognosis and progression. Moreover, our findings highlight PCNA as a promising therapeutic target in PCa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-03309-6","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:37:36Z","timestamp":1766021856000},"page":"662-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Senescence-related gene signature predicts prostate cancer progression and identifies PCNA as a therapeutic target via multi-omics machine learning integration"],"prefix":"10.1038","volume":"134","author":[{"given":"Renxuan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiocheng","family":"Un","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youmei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingwu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4674-7292","authenticated-orcid":false,"given":"Ren","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4925-7232","authenticated-orcid":false,"given":"Zongren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"3309_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"3309_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683\u2013722. https:\/\/doi.org\/10.1016\/S0140-6736(24)00651-2.","journal-title":"Lancet"},{"key":"3309_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur Urol. 2023;84:191\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021.","journal-title":"Eur Urol"},{"key":"3309_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.eururo.2022.01.018","volume":"82","author":"RA Godtman","year":"2022","unstructured":"Godtman RA, Kollberg KS, Pihl CG, M\u00e5nsson M, Hugosson J. The association between age, prostate cancer risk, and higher gleason score in a long-term screening program: results from the g\u00f6teborg-1 prostate cancer screening trial. Eur Urol. 2022;82:311\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2022.01.018.","journal-title":"Eur Urol"},{"key":"3309_CR5","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","volume":"153","author":"C L\u00f3pez-Ot\u00edn","year":"2013","unstructured":"L\u00f3pez-Ot\u00edn C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194\u2013217. https:\/\/doi.org\/10.1016\/j.cell.2013.05.039.","journal-title":"Cell"},{"key":"3309_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41585-021-00496-8","volume":"18","author":"G Fiard","year":"2021","unstructured":"Fiard G, Stavrinides V, Chambers ES, Heavey S, Freeman A, Ball R, et al. Cellular senescence as a possible link between prostate diseases of the ageing male. Nat Rev Urol. 2021;18:597\u2013610. https:\/\/doi.org\/10.1038\/s41585-021-00496-8.","journal-title":"Nat Rev Urol"},{"key":"3309_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188424","volume":"1874","author":"VJ Carpenter","year":"2020","unstructured":"Carpenter VJ, Patel BB, Autorino R, Smith SC, Gewirtz DA, Saleh T. Senescence and castration resistance in prostate cancer: a review of experimental evidence and clinical implications. Biochim Biophys Acta Rev Cancer. 2020;1874:188424. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188424.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3309_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02022-x","volume":"23","author":"T Redmer","year":"2024","unstructured":"Redmer T, Raigel M, Sternberg C, Ziegler R, Probst C, Lindner D, et al. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression. Mol Cancer. 2024;23:114. https:\/\/doi.org\/10.1186\/s12943-024-02022-x.","journal-title":"Mol Cancer"},{"key":"3309_CR9","doi-asserted-by":"publisher","first-page":"00048","DOI":"10.1016\/j.ccell.2024.02.004","volume":"S1535-6108","author":"M Colucci","year":"2024","unstructured":"Colucci M, Zumerle S, Bressan S, Gianfanti F, Troiani M, Valdata A, et al. Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells. Cancer Cell. 2024;S1535-6108:00048\u20135. https:\/\/doi.org\/10.1016\/j.ccell.2024.02.004.","journal-title":"Cancer Cell"},{"key":"3309_CR10","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591\u20137. https:\/\/doi.org\/10.1001\/jama.281.17.1591.","journal-title":"JAMA"},{"key":"3309_CR11","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1200\/JCO.2016.70.2811","volume":"35","author":"DE Spratt","year":"2017","unstructured":"Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, et al. Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease. J Clin Oncol. 2017;35:1991\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.70.2811.","journal-title":"J Clin Oncol"},{"key":"3309_CR12","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.19.02768","volume":"38","author":"SE Eggener","year":"2020","unstructured":"Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, et al. Molecular biomarkers in localized prostate cancer: ASCO guideline. J Clin Oncol. 2020;38:1474\u201394. https:\/\/doi.org\/10.1200\/JCO.19.02768.","journal-title":"J Clin Oncol"},{"key":"3309_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.eururo.2017.09.013","volume":"73","author":"SK Van Den Eeden","year":"2018","unstructured":"Van Den Eeden SK, Lu R, Zhang N, Quesenberry CP, Shan J, Han JS, et al. A Biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease. Eur Urol. 2018;73:129\u201338. https:\/\/doi.org\/10.1016\/j.eururo.2017.09.013.","journal-title":"Eur Urol"},{"key":"3309_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107932","volume":"228","author":"M Adamaki","year":"2021","unstructured":"Adamaki M, Zoumpourlis V. Prostate Cancer biomarkers: from diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther. 2021;228:107932. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107932.","journal-title":"Pharmacol Ther"},{"key":"3309_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis G, Boher JM, Joly F, Souli\u00e9 M, Albiges L, Priou F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70:256\u201362. https:\/\/doi.org\/10.1016\/j.eururo.2015.11.005.","journal-title":"Eur Urol"},{"key":"3309_CR16","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1593\/neo.11182","volume":"13","author":"Z Pernicov\u00e1","year":"2011","unstructured":"Pernicov\u00e1 Z, Slab\u00e1kov\u00e1 E, Kharaishvili G, Bouchal J, Kr\u00e1l M, Kunick\u00e1 Z, et al. Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2. Neoplasia. 2011;13:526\u2013IN13. https:\/\/doi.org\/10.1593\/neo.11182.","journal-title":"Neoplasia"},{"key":"3309_CR17","doi-asserted-by":"publisher","first-page":"e0172048","DOI":"10.1371\/journal.pone.0172048","volume":"12","author":"N Damaschke","year":"2017","unstructured":"Damaschke N, Wagner J, Yang B, Gleave M, Fazli L, et al. Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. PLoS ONE. 2017;12:e0172048 https:\/\/doi.org\/10.1371\/journal.pone.0172048.","journal-title":"PLoS ONE"},{"key":"3309_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ccell.2020.10.012","volume":"39","author":"I Guccini","year":"2021","unstructured":"Guccini I, Revandkar A, D\u2019Ambrosio M, Colucci M, Pasquini E, Mosole S, et al. Senescence reprogramming by TIMP1 deficiency promotes prostate cancer metastasis. Cancer Cell. 2021;39:68\u201382.e9. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.012.","journal-title":"Cancer Cell"},{"key":"3309_CR19","doi-asserted-by":"publisher","first-page":"D825","DOI":"10.1093\/nar\/gkaa894","volume":"49","author":"Aging Atlas Consortium.","year":"2021","unstructured":"Aging Atlas Consortium.. Aging Atlas: a multi-omics database for aging biology. Nucleic Acids Res. 2021;49:D825\u2013D830. https:\/\/doi.org\/10.1093\/nar\/gkaa894.","journal-title":"Nucleic Acids Res"},{"key":"3309_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27.","journal-title":"Nucleic Acids Res"},{"key":"3309_CR21","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2024","unstructured":"Milacic M, Beavers D, Conley P, Gong C, Gillespie M, Griss J, et al. The reactome pathway knowledgebase 2024. Nucleic Acids Res. 2024;52:D672\u2013D678. https:\/\/doi.org\/10.1093\/nar\/gkad1025.","journal-title":"Nucleic Acids Res"},{"key":"3309_CR22","doi-asserted-by":"publisher","first-page":"D1083","DOI":"10.1093\/nar\/gkx1042","volume":"46","author":"R Tacutu","year":"2018","unstructured":"Tacutu R, Thornton D, Johnson E, Budovsky A, Barardo D, Craig T, et al. Human ageing genomic resources: new and updated databases. Nucleic Acids Res. 2018;46:D1083\u2013D1090. https:\/\/doi.org\/10.1093\/nar\/gkx1042.","journal-title":"Nucleic Acids Res"},{"key":"3309_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25\u201329. https:\/\/doi.org\/10.1038\/75556.","journal-title":"Nat Genet"},{"key":"3309_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9:559. https:\/\/doi.org\/10.1186\/1471-2105-9-559.","journal-title":"BMC Bioinform"},{"key":"3309_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26840-5","volume":"12","author":"M Bolis","year":"2021","unstructured":"Bolis M, Bossi D, Vallerga A, Ceserani V, Cavalli M, Impellizzieri D, et al. Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nat Commun. 2021;12:7033. https:\/\/doi.org\/10.1038\/s41467-021-26840-5.","journal-title":"Nat Commun"},{"key":"3309_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206889","volume":"10","author":"D Wang","year":"2023","unstructured":"Wang D, Cheng C, Chen X, Wang J, Liu K, Jing N, et al. IL-1\u03b2 is an androgen-responsive target in macrophages for immunotherapy of prostate cancer. Adv Sci. 2023;10:e2206889. https:\/\/doi.org\/10.1002\/advs.202206889.","journal-title":"Adv Sci"},{"key":"3309_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202305724","volume":"11","author":"X Bian","year":"2024","unstructured":"Bian X, Wang W, Abudurexiti M, Zhang X, Ma W, Shi G, et al. Integration analysis of single-cell multi-omics reveals prostate cancer heterogeneity. Adv Sci. 2024;11:e2305724. https:\/\/doi.org\/10.1002\/advs.202305724.","journal-title":"Adv Sci"},{"key":"3309_CR28","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","volume":"19","author":"CA Schmitt","year":"2022","unstructured":"Schmitt CA, Wang B, Demaria M. Senescence and cancer\u2014role and therapeutic opportunities. Nat Rev Clin Oncol. 2022;19:619\u201336. https:\/\/doi.org\/10.1038\/s41571-022-00668-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"3309_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/pros.24448","volume":"83","author":"S Cheng","year":"2023","unstructured":"Cheng S, Yu X. CTPC, a combined transcriptome data set of human prostate cancer cell lines. Prostate. 2023;83:158\u201361. https:\/\/doi.org\/10.1002\/pros.24448.","journal-title":"Prostate"},{"key":"3309_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58569-w","volume":"16","author":"W Ou","year":"2025","unstructured":"Ou W, Zhang XX, Li B, Tuo Y, Lin RX, Liu PF, et al. Integrated proteogenomic characterization of localized prostate cancer identifies biological insights and subtype-specific therapeutic strategies. Nat Commun. 2025;16:3189. https:\/\/doi.org\/10.1038\/s41467-025-58569-w.","journal-title":"Nat Commun"},{"key":"3309_CR31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","volume":"75","author":"J Campisi","year":"2013","unstructured":"Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685\u2013705. https:\/\/doi.org\/10.1146\/annurev-physiol-030212-183653.","journal-title":"Annu Rev Physiol"},{"key":"3309_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.semcancer.2011.09.013","volume":"21","author":"R Saab","year":"2011","unstructured":"Saab R. Senescence and pre-malignancy: how do tumors progress? Semin Cancer Biol. 2011;21:385\u201391. https:\/\/doi.org\/10.1016\/j.semcancer.2011.09.013.","journal-title":"Semin Cancer Biol"},{"key":"3309_CR33","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/med.21333","volume":"35","author":"H Aloysius","year":"2015","unstructured":"Aloysius H, Hu L. Targeted prodrug approaches for hormone refractory prostate cancer. Med Res Rev. 2015;35:554\u201385. https:\/\/doi.org\/10.1002\/med.21333.","journal-title":"Med Res Rev"},{"key":"3309_CR34","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.2165\/00003495-200565160-00003","volume":"65","author":"K McKeage","year":"2005","unstructured":"McKeage K, Keam SJ. Docetaxel in hormone-refractory metastatic prostate cancer. Drugs. 2005;65:2287\u201394. https:\/\/doi.org\/10.2165\/00003495-200565160-00003.","journal-title":"Drugs"},{"key":"3309_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1631\/jzus.2007.B0377","volume":"8","author":"E Schmitt","year":"2007","unstructured":"Schmitt E, Paquet C, Beauchemin M, Bertrand R. DNA-damage response network at the crossroads of cell-cycle checkpoints, cellular senescence and apoptosis. J Zhejiang Univ Sci B. 2007;8:377\u201397. https:\/\/doi.org\/10.1631\/jzus.2007.B0377.","journal-title":"J Zhejiang Univ Sci B"},{"key":"3309_CR36","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/stem.1943","volume":"33","author":"H Yousef","year":"2015","unstructured":"Yousef H, Morgenthaler A, Schlesinger C, Bugaj L, Conboy IM, Schaffer DV. Age-associated increase in BMP signaling inhibits hippocampal neurogenesis. Stem Cells. 2015;33:1577\u201388. https:\/\/doi.org\/10.1002\/stem.1943.","journal-title":"Stem Cells"},{"key":"3309_CR37","doi-asserted-by":"publisher","first-page":"8274","DOI":"10.1158\/0008-5472.CAN-05-1891","volume":"65","author":"J Dai","year":"2005","unstructured":"Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 2005;65:8274\u201385. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1891.","journal-title":"Cancer Res"},{"key":"3309_CR38","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1002\/cbic.202100118","volume":"22","author":"S Wang","year":"2021","unstructured":"Wang S, Alpsoy A, Sood S, Ordonez-Rubiano SC, Dhiman A, Sun Y, et al. A potent, selective CBX2 chromodomain ligand and its cellular activity during prostate cancer neuroendocrine differentiation. Chembiochem. 2021;22:2335\u201344. https:\/\/doi.org\/10.1002\/cbic.202100118.","journal-title":"Chembiochem"},{"key":"3309_CR39","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1158\/0008-5472.CAN-25-0636","volume":"85","author":"VB Venkadakrishnan","year":"2025","unstructured":"Venkadakrishnan VB, Presser A, Voss NCE, Neiswender J, Brenan L, Sosa KP, et al. Epigenetic derepression of PROX1 promotes neuroendocrine prostate cancer progression. Cancer Res. 2025;85:3842\u201354. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-0636.","journal-title":"Cancer Res"},{"key":"3309_CR40","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s41418-018-0198-0","volume":"26","author":"LG Ju","year":"2019","unstructured":"Ju LG, Zhu Y, Long QY, Li XJ, Lin X, Tang SB, et al. SPOP suppresses prostate cancer through regulation of CYCLIN E1 stability. Cell Death Differ. 2019;26:1156\u201368. https:\/\/doi.org\/10.1038\/s41418-018-0198-0.","journal-title":"Cell Death Differ"},{"key":"3309_CR41","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3892\/etm.2023.12212","volume":"26","author":"Y Huang","year":"2023","unstructured":"Huang Y, Zhang L, Liu T, Liang E. LMNB1 targets FOXD1 to promote progression of prostate cancer. Exp Ther Med. 2023;26:513 https:\/\/doi.org\/10.3892\/etm.2023.12212.","journal-title":"Exp Ther Med"},{"key":"3309_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101708","volume":"35","author":"K Gao","year":"2023","unstructured":"Gao K, Zhu S, Shao Q, Qi Y, Zhang C, Li X, et al. DNA repair pathways-targeted cyclovirobuxine inhibits castration-resistant prostate cancer growth by promoting cell apoptosis and cycle arrest. Transl Oncol. 2023;35:101708. https:\/\/doi.org\/10.1016\/j.tranon.2023.101708.","journal-title":"Transl Oncol"},{"key":"3309_CR43","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/emboj.2011.154","volume":"30","author":"Z Chen","year":"2011","unstructured":"Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, et al. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J. 2011;30:2405\u201319. https:\/\/doi.org\/10.1038\/emboj.2011.154.","journal-title":"EMBO J"},{"key":"3309_CR44","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.25011\/cim.v31i1.3136","volume":"31","author":"W Zhong","year":"2008","unstructured":"Zhong W, Peng J, He H, Wu D, Han Z, Bi X, et al. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Investig Med. 2008;31:E8\u2013E15. https:\/\/doi.org\/10.25011\/cim.v31i1.3136.","journal-title":"Clin Investig Med"},{"key":"3309_CR45","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3390\/biom10040570","volume":"10","author":"A Gonz\u00e1lez-Maga\u00f1a","year":"2020","unstructured":"Gonz\u00e1lez-Maga\u00f1a A, Blanco FJ. Human PCNA Structure, function and interactions. Biomolecules. 2020;10:570 https:\/\/doi.org\/10.3390\/biom10040570.","journal-title":"Biomolecules"},{"key":"3309_CR46","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.tips.2014.02.004","volume":"35","author":"SC Wang","year":"2014","unstructured":"Wang SC. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharm Sci. 2014;35:178\u201386. https:\/\/doi.org\/10.1016\/j.tips.2014.02.004.","journal-title":"Trends Pharm Sci"},{"key":"3309_CR47","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"Y He","year":"2022","unstructured":"He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7:198 https:\/\/doi.org\/10.1038\/s41392-022-01042-7.","journal-title":"Signal Transduct Target Ther"},{"key":"3309_CR48","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.tig.2022.02.010","volume":"38","author":"PL Vaddavalli","year":"2022","unstructured":"Vaddavalli PL, Schumacher B. The p53 network: cellular and systemic DNA damage responses in cancer and aging. Trends Genet. 2022;38:598\u2013612. https:\/\/doi.org\/10.1016\/j.tig.2022.02.010.","journal-title":"Trends Genet"},{"key":"3309_CR49","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1093\/nar\/gkae061","volume":"52","author":"BA Casta\u00f1o","year":"2024","unstructured":"Casta\u00f1o BA, Schorer S, Guo Y, Calzetta NL, Gottifredi V, Wiesm\u00fcller L, et al. The levels of p53 govern the hierarchy of DNA damage tolerance pathway usage. Nucleic Acids Res. 2024;52:3740\u201360. https:\/\/doi.org\/10.1093\/nar\/gkae061.","journal-title":"Nucleic Acids Res"},{"key":"3309_CR50","doi-asserted-by":"publisher","first-page":"e0223894","DOI":"10.1371\/journal.pone.0223894","volume":"14","author":"S Lu","year":"2019","unstructured":"Lu S, Dong Z. Additive effects of a small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells. PLoS ONE. 2019;14:e0223894 https:\/\/doi.org\/10.1371\/journal.pone.0223894.","journal-title":"PLoS ONE"},{"key":"3309_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111510","volume":"125","author":"X Shu","year":"2025","unstructured":"Shu X, Yi J, Li J, Ying Y, Tang Y, Chen Z, et al. N6-methyladenosine-modified circRPS6KC1 regulated cellular senescence in prostate cancer via FOXM1\/PCNA axis. Cell Signal. 2025;125:111510. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111510.","journal-title":"Cell Signal"},{"key":"3309_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/1535-7163.MCT-10-0778","volume":"10","author":"H Zhao","year":"2011","unstructured":"Zhao H, Lo YH, Ma L, Waltz SE, Gray JK, Hung MC, et al. Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth. Mol Cancer Ther. 2011;10:29\u201336. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0778.","journal-title":"Mol Cancer Ther"},{"key":"3309_CR53","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.chembiol.2023.07.001","volume":"30","author":"L Gu","year":"2023","unstructured":"Gu L, Li M, Li CM, Haratipour P, Lingeman R, Jossart J, et al. Small molecule targeting of transcription-replication conflict for selective chemotherapy. Cell Chem Biol. 2023;30:1235\u2013.e6. https:\/\/doi.org\/10.1016\/j.chembiol.2023.07.001.","journal-title":"Cell Chem Biol"},{"key":"3309_CR54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s40164-024-00586-4","volume":"13","author":"H Kang","year":"2024","unstructured":"Kang H, Valerio M, Feng J, Gu L, Hoang DH, Blackmon A, et al. AOH1996 targets mitochondrial dynamics and metabolism in leukemic stem cells via mitochondrial PCNA inhibition. Exp Hematol Oncol. 2024;13:123 https:\/\/doi.org\/10.1186\/s40164-024-00586-4.","journal-title":"Exp Hematol Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03309-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03309-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03309-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:54:58Z","timestamp":1769770498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03309-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,20]]}},"alternative-id":["3309"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03309-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}